Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"
Jump to navigation
Jump to search
Template documentation
imported>Medgirl131 |
imported>Medgirl131 (Restore table centering another way. Please let me know if there is a better way to do this.) |
||
| Line 1: | Line 1: | ||
| + | <center> | ||
{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" | {| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" | ||
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative | |+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative | ||
| Line 31: | Line 32: | ||
|- class="sortbottom" | |- class="sortbottom" | ||
| colspan="10" style="background-color:#eaecf0; text-align: center;" | '''Sources:''' <noinclude><ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref></noinclude><includeonly>See template.</includeonly> | | colspan="10" style="background-color:#eaecf0; text-align: center;" | '''Sources:''' <noinclude><ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref></noinclude><includeonly>See template.</includeonly> | ||
| − | |}<!-- | + | |} |
| + | </center><!-- | ||
--><noinclude>{{Documentation|content= | --><noinclude>{{Documentation|content= | ||
Revision as of 09:08, 1 April 2019
| Event | Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI[note 1]) | Placebo (n = 8102) |
CEEs/MPA (n = 8506) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Absolute Risk per 10,000 Women-Years | |||||||||
| Coronary heart disease events ( non-fatal myocardial infarction, death) |
1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) |
30 23 6 |
37 30 7 | ||||||
| Invasive breast cancer[lower-alpha 1] | 1.26 (1.00–1.59) | 30 | 38 | ||||||
| Stroke | 1.41 (1.07–1.85) | 21 | 29 | ||||||
| Pulmonary embolism | 2.13 (1.39–3.25) | 8 | 16 | ||||||
| Colorectal cancer | 0.63 (0.43–0.92) | 16 | 10 | ||||||
| Endometrial cancer | 0.83 (0.47–1.47) | 6 | 5 | ||||||
| Hip fracture | 0.66 (0.45–0.98) | 15 | 10 | ||||||
| Death due to causes other than above | 0.92 (0.74–1.14) | 40 | 37 | ||||||
| Global Index[lower-alpha 2] | 1.15 (1.03–1.28) | 151 | 170 | ||||||
| Deep vein thrombosis[lower-alpha 3] | 2.07 (1.49–2.87) | 13 | 26 | ||||||
| Vertebral fractures[lower-alpha 3] | 0.66 (0.44–0.98) | 15 | 9 | ||||||
| Other osteoporotic fractures[lower-alpha 3] | 0.77 (0.69–0.86) | 170 | 131 | ||||||
| Sources: [1][2] | |||||||||
| This template's documentation is missing, inadequate, or does not accurately describe its functionality and/or the parameters in its code. Please help to expand and improve it. (March 2019) |
Notes and references
- ↑ Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.
- ↑ A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
- ↑ 3.0 3.1 3.2 Not included in Global Index.
- ↑ Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
- ↑ Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |
Cite error: <ref> tags exist for a group named "note", but no corresponding <references group="note"/> tag was found, or a closing </ref> is missing